Flashback Foreword: Preoperative Therapy for Operable Breast Cancer and Clinical Features of Triple-Negative Breast Cancer
- PMID: 36989608
- DOI: 10.1200/JCO.22.02784
Flashback Foreword: Preoperative Therapy for Operable Breast Cancer and Clinical Features of Triple-Negative Breast Cancer
Similar articles
-
[A Useful Method of Nipple-Side HydroMARK-Marking before Neoadjuvant Chemotherapy in the Breast Preserving Surgery-A Case Report with pCR of the Triple Negative Breast Cancer].Gan To Kagaku Ryoho. 2021 Mar;48(3):440-442. Gan To Kagaku Ryoho. 2021. PMID: 33790181 Japanese.
-
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.Int J Cancer. 2016 May 1;138(9):2274-80. doi: 10.1002/ijc.29952. Epub 2015 Dec 28. Int J Cancer. 2016. PMID: 26649807 Clinical Trial.
-
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.Ann Oncol. 2014 Aug;25(8):1570-7. doi: 10.1093/annonc/mdu183. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827135 Clinical Trial.
-
When and how do I use neoadjuvant chemotherapy for breast cancer?Curr Treat Options Oncol. 2014 Mar;15(1):86-98. doi: 10.1007/s11864-013-0266-0. Curr Treat Options Oncol. 2014. PMID: 24306808 Review.
-
Chimiothérapie néo-adjuvante des cancers du sein HER2-positifs et triple-négatifs.Bull Cancer. 2016 Jun;103(6 Suppl 1):S76-89. doi: 10.1016/S0007-4551(16)30149-7. Bull Cancer. 2016. PMID: 27494978 Review. French.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical